While dysregulation of EZH2 activity in hematological malignancies is predominantly caused by activating mutations [36,37], abundance of the methyltransferase in solid cancers including PDAC is mainly linked to overexpression [7,12,28,29,30,31,32]. Here, EZH2 is linked to hematologic disorder.